CVS Health
Q2 2026, reported August 5, showed revenue of $106.1B (+7.3% YoY), adjusted EPS of $2.58 versus $1.81 and a Health Care Benefits medical benefit ratio of 87.4%, down 250bps, as the Aetna margin recovery took hold; full-year guidance was raised to adjusted EPS of $7.90-8.10, revenue of at least $414B and operating cash flow of at least $11.5B. The earnings rebound is insurance repricing, not AI. AI is applied to administrative cost — agentic AI in Aetna and Caremark call centers, a second-generation Claims Assist Manager that the company says cuts complex-claim processing time by more than 20%, and AI prescription interpretation in pharmacy dispensing. Health100, the AI-native consumer engagement platform built with Google Cloud and unveiled at the December 2025 investor day, remains pre-scale, with a personal AI assistant planned and no adoption metrics disclosed.
Scenarios
Owning the insurer, PBM, pharmacy and care-delivery layers gives it more claims, prescription and engagement data than any AI-native entrant. If Health100 turns that into a single AI-driven consumer front door, administrative savings and member retention compound across all three segments.
The 2026 rebound is pricing-driven and fragile — management cites elevated cost trends and macro headwinds, and flags 2027 pressure from 340B and lower Caremark membership. PBM reform remains a bipartisan target, Amazon and Walmart pressure retail pharmacy, and the AI program has no disclosed P&L contribution beyond process metrics.
Key Factors to Watch
- ●Q2 2026 (Aug 5) — revenue $106.1B (+7.3%), adj EPS $2.58, HCB MBR 87.4% (-250bps); FY26 adj EPS guide raised to $7.90-8.10, revenue at least $414B
- ●Agentic AI in Aetna and Caremark call centers; Claims Assist Manager gen-2 cuts complex-claim processing time >20% (company-reported)
- ●Health100 with Google Cloud is the defining AI bet — personal AI assistant planned, no adoption metrics yet
- ●2027 headwinds (340B pressure, lower Caremark membership) and PBM reform risk are independent of AI
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-10-10 | 5.4 | Neutral | W41 rotation refresh — score holds 5.4, no dim change. Rebased on Q2 2026 8-K (Aug 5) — revenue $106.1B, adj EPS $2.58, MBR 87.4%, FY guide $7.90-8.10 and revenue at least $414B (replaces stale $400B+ / operating-income guide). AI evidence is process-level (agentic call centers, Claims Assist gen-2 >20% faster); removed unverified $2B-by-2028 AI savings, stale Aetna-loss claim and $80 price target. No AI event after Aug 22. |
| 2026-03-08 | 5.4 | Neutral | Score 5.7→5.4 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 5.7 | Neutral | Initial assessment from batch 9 blind spot review |
Healthcare Peers
Last researched: 2026-10-10
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.